Five things for pharma marketers to know: Tuesday, January 23, 2018
1. The FDA issued new policies aimed at improving manufacturing standards for compounded drugs. They include a new rule that prevents compounders from copying FDA-approved drugs unless there are shortages. (Stat)
2. Doctors at the University of Pennsylvania said they plan to test gene-editing tool CRISPR on 18 cancer patients. It would represent the first medical use of CRISPR outside China. (MIT Technology Review)
3. Syneos Health Communications has merged Palio into sibling agency GSW. Sonja Foster-Storch will remain president of GSW North America, while Palio president Kim Johnson becomes president of GSW New York and Santa Monica.
4. The FDA rejected Braeburn Pharmaceuticals' experimental opioid-addiction drug CAM2038 and requested that the drugmaker provide additional information. The setback benefits competitors, including Indivior's Suboxone and Alkermes' Vivitrol. (Endpoints News)
5. Ambiguous language in the Medicaid Drug Rebate Program signed by President George H.W. Bush may have led drugmakers to overcharge the government for generic drugs, according to some legal experts. (Stat)